Laidlaw & Co. Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $22
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Laidlaw & Co. analyst Yale Jen initiates coverage on Nasus Pharma (AMEX:NSRX) with a Buy rating and announces Price Target of $22.
Laidlaw & Co. analyst Yale Jen initiates coverage on Nasus Pharma (AMEX:NSRX) with a Buy rating and announces Price Target of $22.